Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2019 / N 2

Кандесартан: выход за пределы сердечно-сосудистого континуума
Ю.А. Карпов, А.В. Мелехов

References

1. Hübner R, Högemann AM, Sunzel M, Riddell JG. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. Journal of Human Hypertension 1997 Sep;11(Suppl 2):S19-25.
2. Inada Y, Ojima M, Kanagawa R, Misumi Y, Nishikawa K, Naka T. Pharmacologic properties of candesartan cilexetil – possible mechanisms of long-acting antihypertensive action. Journal of Human Hypertension 1999 Jan;13(Suppl 1):S75-80.
3. Unger T. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil. Blood Pressure. Supplement 2000;1:14-8.
4. Vauquelin G, Fierens FL, Verheijen I, Vanderheyden PM. Distinctions between non-peptide angiotensin II AT1-receptor antagonists. Journal of the Renin-Angiotensin-Aldosterone System: JRAAS 2001 Mar;2(1_suppl):S24-31.
5. Van Lier JJ, van Heiningen PN, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. Journal of Human Hypertension 1997 Sep;11(Suppl 2):S27-8.
6. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). Journal of Hypertension 2003 Aug;21(8):1563-74.
7. Imbs JL, Nisse-Durgeat S; French Collaborative Candesartan Study Group. Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients International Journal of Clinical Practice 2005 Jan;59(1):78-84.
8. Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. American Journal of Hypertension 2000 May;13(5 Pt 1):504-11.
9. Derosa G, Cicero AF, Ciccarelli L, Fogari R. A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clinical Therapeutics 2003 Jul;25(7):2006-21.
10. Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S, Vendetti J, Michelson EL, Wang R; CLAIM Study Investigators. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. The Journal of Clinical Hypertension 2001 Jan-Feb;3(1):16-21.
11. Vidt DG, White WB, Ridley E, Rahman M, Harris S, Vendetti J, Michelson EL, Wang R; CLAIM Study Investigators. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. Journal of Human Hypertension 2001 Jul;15(7):475-80.
12. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Pressure 1998 Jan;7(1):53-9.
13. Gradman AH, Lewin A, Bowling BT, Tonkon M, Deedwania PC, Kezer AE, Hardison JD, Cushing DJ, Michelson EL. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Disease 1999 May-Jun;1(2):52-7.
14. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. American Journal of Hypertension 1999 Dec;12(12 Pt 1-2):1181-7.
15. Zhenfeng Zheng, Huilan Shi, Junya Jia, Dong Li, Shan Lin. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. Journal of the Renin-Angiotensin-Aldosterone System: JRAAS 2011 Sep;12(3):365-74.
16. Zhao D, Liu H, Dong P. A meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension. Clinical and Experimental Hypertension: CHE 2019;41(1):75-9.
17. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, Bunt AM. Angiotensin II antagonists for hypertension: are there differences in efficacy? American Journal of Hypertension 2000 Apr;13(4 Pt 1):418-26.
18. Tsoi B, Akioyamen LE, Bonner A, Frankfurter C, Levine M, Pullenayegum E, Goeree R, O'Reilly D. Comparative efficacy of angiotensin II antagonists in essential hypertension: systematic review and network meta-analysis of randomised controlled trials. Heart, Lung & Circulation 2018 Jun;27(6):666-82.
19. Pang XF, Liu RM, Xia YF. Effects of inhibitors of the renin-angiotensin system on reducing blood pressure and expression of inflammatory factors in CHD patients: a network meta-analysis. Journal of Cellular Physiology 2019 May;234(5):5988-97.
20. Meredith P, Trenkwalder P. Angiotensin II antagonists for hypertension: there are differences in efficacy. American Journal of Hypertension 2001 Apr;14(4 Pt 1):394-6.
21. Shimizu M, Ishikawa J, Yano Y, Hoshide S, Eguchi K, Ishikawa S, Shimada K, Kario K. Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study. Journal of Hypertension 2012 May;30(5):1015-21.
22. Hasegawa H, Takano H, Kameda Y, Kubota A, Kobayashi Y, Komuro I. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clinical and Experimental Hypertension: CHE 2012;34(2):86-91.
23. Minatoguchi S, Aoyama T, Kawai N, Iwasa M, Oda M, Kida K, Kojima S, Goto N, Goto M, Sugishita F, Takai K, Tanaka R, Hiei K, Minagawa T, Yamamoto N, Watanabe I, Yasue T, Kobayashi H. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Pressure 2013 Sep;22(Suppl 1):29-37.
24. Weisser B, Gerwe M, Braun M, Funken C. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals]. Arzneimittel-Forschung 2005;55(9):505-13.
25. Escobar C, Barrios V, Calderón A, Barrios S, Echarri R, Navarro-Cid J, Ferrer E, Fernandez R. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. The Journal of Clinical Hypertension 2008 Mar;10(3):208-14.
26. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, Magnani B, Zanchetti A; CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. Journal of Hypertension 2002 Nov;20(11):2293-300.
27. De Rosa ML, Chiariello M. Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial. Journal of Clinical Hypertension 2009 Apr;11(4):192-200.
28. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. British Medical Journal 2000 Dec;321(7274):1440-4.
29. Okura T, Kojima M, Machida H, Sugiyama M, Kato T, Komada T, Miyazaki T, Ninomiya T, Ichikawa T, Nakatani K, Watanabe Y, Dohi Y, Ito M, Kimura G. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. Journal of Human Hypertension 2012 Apr;26(4):214-9.
30. Kohagura K, Arima H, Miyasato H, Chang TH, Yamazato M, Kobori H, Nishiyama A, Iseki K, Ohya Y. Add-on effect of angiotensin receptor blockade (candesartan) on clinical remission in active IgA nephropathy patients treated with steroid pulse therapy and tonsillectomy: a randomized, parallel-group comparison trial. Kidney & Blood Pressure Research 2018;43(3):780-92.
31. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension 2003 May;21(5):875-86.
32. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). American Journal of Hypertension 2005 Aug;18(8):1052-9.
33. Perez-Lloret S, Otero-Losada M, Toblli JE, Capani F. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease. Expert Opinion on Investigational Drugs 2017 Oct;26(10):1163-73.
34. Mecca AP, O’Connor TE, Katovich MJ, Sumners C. Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. Experimental Physiology 2009 Aug;94(8):937-46.
35. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008 Oct;372(9647):1394-402.
36. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008 Oct;372(9647):1385-93.
37. Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme. Eye 2010 Jan;24(1):1-6.
38. Ogihara T, Fujimoto A, Nakao K, Saruta T; CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Review of Cardiovascular Therapy 2008 Oct;6(9):1195-201.
39. Ogihara T, Ueshima K, Nakao K, Fukiyama K, Oba K, Yasuno S, Fujimoto A, Sato T, Matsuoka H, Saruta T; CASE-J Ex Study Group. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research: Official Journal of the Japanese Society of Hypertension 2011 Dec;34(12):1295-301.
40. Nakao K, Hirata M, Oba K, Yasuno S, Ueshima K, Fujimoto A, Ogihara T, Saruta T; CASE-J Trial Group. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. Hypertension Research: Official Journal of the Japanese Society of Hypertension 2010 Jun;33(6):600-6.
41. Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H; HIJ-CREATE Investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). European Heart Journal 2009 May;30(10):1203-12.
42. Russell D, Stålhammar J, Bodegard J, Hasvold P, Thuresson M, Kjeldsen SE. Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan. Journal of Clinical Hypertension 2011 Mar;13(3):189-97.
43. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003 Sep;362(9386):759-66.
44. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, Olofsson B, Ostergren J, Yusuf S. Candesartan in heart failure–assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. Journal of Cardiac Failure 1999 Sep;5(3):276-82.
45. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003 Sep;362(9386):777-81.
46. Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005 Dec;112(24):3738-44.
47. Mele D, Nardozza M, Ferrari R. Left ventricular ejection fraction and heart failure: an indissoluble marriage? European Journal of Heart Failure 2018 Mar;20(3):427-30.
48. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon SD. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure 2018 Aug;20(8):1230-9.
49. Nauta JF, Hummel YM, van Melle JP, van der Meer P, Lam CSP, Ponikowski P, Voors AA. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? European Journal of Heart Failure 2017 Dec;19(12):1569-73.
50. Takahama H, Asakura M, Abe Y, Ajioka M, Aonuma K, Anzai T, Hayashi T, Hiramitsu S, Kawai H, Kioka H, Kimura K, Lim YJ, Matsuoka K, Motoki H, Nagata Y, Nakamura S, Ohte N, Ozaki Y, Sasaoka T, Tamaki S, Hamasaki T, Kitakaze M; J-TASTE investigators. Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial. Cardiovascular Drugs and Therapy 2018 Aug;32(4):381-8.
51. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hagve TA, Røsjø H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. European Heart Journal 2016 Jun;37(21):1671-80.
52. Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Storås TH, Ree AH, Gravdehaug B, Røsjø H, Steine K, Geisler J, Schulz-Menger J, Omland T. Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. European Heart Journal Cardiovascular Imaging 2018 May;19(5):544-52.
53. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal 2016 Sep;37(36):2768-801.
54. Гендлин Г.Е., Емелина Е.И., Никитин И.Г., Васюк Ю.А. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. Российский кардиологический журнал 2017;3(143):145-54.
55. Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncology 2016 Aug;2(8):1030-7.
56. Sherif IO, Sarhan OM. Candesartan in a rat model of testicular toxicity: new insight on its protective mechanism. Experimental Biology and Medicine 2019 May;244(7):593-601.
57. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. Journal of the American Medical Association 2003 Jan;289(1):65-9.
58. Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, Hagen K. A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia: an International Journal of Headache 2014 Jun;34(7):523-32.
59. Dorosch T, Ganzer CA, Lin M, Seifan A. Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults. Current Pain and Headache Reports 2019 Sep;23(11):85.
60. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 2019 Jan;59(1):1-18.
61. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. European Journal of Neurology 2009 Sep;16(9):968-81.
62. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012 Apr;78(17):1337-45.
63. Gronseth GH, Cox J, Getchius TSD. Amendments to the 2011 American Academy of Neurology Clinical Practice Guideline Process Manual. Available from: https://www.aan.com/siteassets/home-page/policy-and-guidelines/guidelines/about-guidelines/15processmanualamendment_v607.pdf Accessed 2018 Oct 26.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]